Halozyme Therapeutics, Inc. (HALO) News
Filter HALO News Items
HALO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
HALO News Highlights
- For HALO, its 30 day story count is now at 5.
- Over the past 10 days, the trend for HALO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about HALO are TOP.
Latest HALO News From Around the Web
Below are the latest news stories about HALOZYME THERAPEUTICS INC that investors may wish to consider to help them evaluate HALO as an investment opportunity.
Insider Sell Alert: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of ...Halozyme Therapeutics Inc (NASDAQ:HALO), a biopharmaceutical company known for its novel enzyme technology that targets the extracellular matrix, has recently witnessed a significant insider sell transaction. |
3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market. |
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-TermWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
Why Is Halozyme Therapeutics (HALO) Up 2.8% Since Last Earnings Report?Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Here's Why Halozyme Therapeutics (HALO) is a Strong Value StockWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
Halozyme to Present at Upcoming Investor ConferencesHalozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the senior leadership team are scheduled to present and host investor meetings at the following investor conferences. |
Here is Why Growth Investors Should Buy Halozyme Therapeutics (HALO) NowHalozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes. |
Halozyme Therapeutics' (NASDAQ:HALO) 20% CAGR outpaced the company's earnings growth over the same five-year periodWhen you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really... |
Are You a Growth Investor? This 1 Stock Could Be the Perfect PickThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
Can Halozyme Therapeutics (HALO) Climb 28.72% to Reach the Level Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 28.7% in Halozyme Therapeutics (HALO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |